To be enrolled in the PARADIGM-HF active run-in phase, patients had to be treated with a dose of ACE inhibitor or ARB equivalent to enalapril 10 mg daily—we further identified the subset of patients in SwedeHF treated in this way (scenario 2). The gene discussed is ACE; the disease is hydrops fetalis.